Paper Details

  1. Home
  2. Paper Details

Methotrexate in polymyalgia rheumatica: preliminary results of an open, randomized study.

Author: BartoliE, CasattaL, De VitaS, FerraccioliG, SalaffiF

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Adding methotrexate to prednisone therapy for polymyalgia rheumatica (PMR) allowed for significantly lower prednisone doses while maintaining efficacy and reducing bone loss.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: Steroids are the only treatment of polymyalgia rheumatica (PMR). We report the effects of methotrexate (MTX) plus prednisone versus prednisone alone in PMR. METHODS: Twenty-four patients with recent onset PMR were studied in a randomized prospective study lasting one year. Patients were ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/8730115

データ提供：米国国立医学図書館（NLM）

Easing the Pain of Polymyalgia Rheumatica: Methotrexate as a Treatment Option

Polymyalgia rheumatica (PMR) is a painful inflammatory condition that primarily affects the muscles and joints. This study explores the potential of methotrexate (MTX) as a treatment option for PMR, comparing its effectiveness to prednisone alone. The study found that MTX combined with prednisone was more effective in controlling PMR symptoms than prednisone alone. This was evidenced by a significantly lower prednisone dosage required to achieve clinical remission and a reduced risk of bone loss in patients treated with MTX. These findings suggest that MTX could be a valuable treatment option for PMR, particularly for older patients who are at increased risk of osteoporosis.

A New Path to Relief: Minimizing Prednisone Use

This study offers a promising alternative for patients with PMR, potentially reducing the need for high doses of prednisone and its associated side effects. The use of MTX in combination with prednisone could significantly improve the quality of life for patients with PMR, enabling them to manage their condition more effectively and minimize the long-term risks associated with high-dose steroid therapy.

Building Stronger Bones: Combating PMR-Related Osteoporosis

The study highlights the importance of considering the impact of PMR treatment on bone health. The use of MTX in combination with prednisone has the potential to protect bone density, a significant benefit for older patients who are at increased risk of osteoporosis. This emphasizes the need for comprehensive management of PMR, addressing not only the immediate symptoms but also the long-term health implications of the disease.

Dr.Camel's Conclusion

Much like a camel's strong legs allow it to traverse harsh desert terrain, MTX combined with prednisone could provide a strong foundation for managing PMR. The study offers a promising alternative to high-dose steroid therapy, potentially minimizing side effects and improving bone health, ensuring that the journey to recovery is as smooth and sustainable as a camel's trek through the sand.
Date :
  1. Date Completed 1996-09-25
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

8730115

DOI: Digital Object Identifier

8730115

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.